Literature DB >> 23375432

Intrathoracic subclavian artery aneurysm repair in the thoracic endovascular aortic repair era.

Nicholas D Andersen1, Michael E Barfield, Jennifer M Hanna, Asad A Shah, Cynthia K Shortell, Richard L McCann, G Chad Hughes.   

Abstract

OBJECTIVE: Intrathoracic subclavian artery aneurysms (SAAs) are rare aneurysms that often occur in association with congenital aortic arch anomalies and/or concomitant thoracic aortic pathology. The advent of thoracic endovascular aortic repair (TEVAR) methods may complement or replace conventional open SAA repair. Herein, we describe our experience with SAA repair in the TEVAR era.
METHODS: A retrospective review was performed of all intrathoracic SAAs repaired at a single institution since United States Food and Drug Administration approval of TEVAR in 2005.
RESULTS: Nineteen patients underwent 20 operations to repair 22 (13 native, nine aberrant) SAAs with an intrathoracic component. Mean SAA diameter was 3.1 cm (range, 1.6-6.0 cm). Mean patient age was 57 years (range, 24-80 years). Twenty-one percent (n = 4) of patients had a connective tissue disorder (two Loeys-Dietz, two Marfan). Thirty-six percent (n = 8) of SAAs were repaired by open techniques and 64% (n = 14) via a TEVAR-based approach. All TEVAR cases required proximal landing zone in the aortic arch (zone 0-2), and revascularization of at least one arch vessel was required in 83% (10/12) of patients. Concomitant repair of associated aortic pathology was performed in 50% (n = 10) of operations. Thirty-day/in-hospital rates of death, stroke, and permanent paraplegia/paraparesis were 5% (n = 1), 5% (n = 1), and 0%, respectively. Over mean (standard deviation) follow-up of 24 (21) months, 16% (n = 3) of patients required reintervention for subclavian artery bypass graft revision (n = 2) or type II endoleak (n = 1).
CONCLUSIONS: This is the largest single-institution series to date of TEVAR for SAA repair. Modern endovascular techniques expand SAA repair options with excellent results. The majority of SAAs and nearly all aberrant SAAs (Kommerell's diverticulum) can now be repaired using a TEVAR-based approach without the need for sternotomy or thoracotomy.
Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23375432     DOI: 10.1016/j.jvs.2012.09.074

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

Review 1.  Kommerell's diverticulum in the current era: a comprehensive review.

Authors:  Akiko Tanaka; Ross Milner; Takeyoshi Ota
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-31

2.  Hybrid Repair of Proximal Subclavian Artery Aneurysm.

Authors:  Kazuki Morimoto; Hitoshi Matsuda; Tetsuya Fukuda; Hiroshi Iba; Hiroshi Tanaka; Hiroaki Sasaki; Kenji Minatoya; Junjiro Kobayashi
Journal:  Ann Vasc Dis       Date:  2015-05-26

3.  Pathology-specific secondary aortic interventions after thoracic endovascular aortic repair.

Authors:  Salvatore T Scali; Adam W Beck; Khayree Butler; Robert J Feezor; Tomas D Martin; Philip J Hess; Thomas S Huber; Catherine K Chang
Journal:  J Vasc Surg       Date:  2014-03       Impact factor: 4.268

Review 4.  [Rare aortic diseases: infections, tumors, congenital anomalies].

Authors:  P Erhart; M Wortmann; C Wieker; B Kovács; M Wehrmeister; D Böckler
Journal:  Chirurg       Date:  2014-09       Impact factor: 0.955

5.  Successful treatment of a ruptured subclavian artery aneurysm presenting as hemoptysis with a covered stent.

Authors:  Sung Soo Kim; Myung Ho Jeong; Ji Eun Kim; Yi Rang Yim; Hyuk Jin Park; Seung Hun Lee; Shi Hyun Rhew; Young Wook Jeong; Ju Han Kim; Jeong Gwan Cho; Jong Chun Park
Journal:  Chonnam Med J       Date:  2014-08-20

6.  A Systematic Review of Total Thoracic Endovascular Aortic Repair in Treatment of Kommerell Diverticulum Combined with Right-Sided Aortic Arch.

Authors:  Weijian Fan; Jinyun Tan; Weihao Shi; Jianjie Rong; Bo Yu
Journal:  Med Sci Monit       Date:  2021-03-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.